Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 14-21

  Leite, Paula Mendonça ^a   Martins, Maria Auxiliadora Parreiras ^a   Castilho, Rachel Oliveira ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anticoagulants; Blood coagulation; Drug herb interaction; Medicinal plants

Indexed keywords

ARACHIDONIC ACID; COUMARIN DERIVATIVE; HERBACEOUS AGENT; LIGNAN; QUINONE DERIVATIVE; TERPENE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VITAMIN K GROUP; WARFARIN; XANTHONE DERIVATIVE; ANTICOAGULANT AGENT;

ALFALFA; ALOE VERA; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TRANSFORMATION; FIBRINOLYSIS; GARLIC; GINGER; GINKGO BILOBA; GINSENG; HEMOSTASIS; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; MEDICINAL PLANT; PHYTOCHEMISTRY; PLANTAGO OVATA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; CHEMISTRY; TREATMENT OUTCOME;

ANTICOAGULANTS; HERB-DRUG INTERACTIONS; HUMANS; PLANTS, MEDICINAL; TREATMENT OUTCOME; WARFARIN;

EID: 84974824015     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.06.012     Document Type: Review

References (54)

1. Brandão M.G.L., Grael C.F.F., Fagg C.W. European naturalists and medicinal plants in Brazil. Biological Diversity and Sustainable Resources Use 2011, 101-120. In Tech, Rijeka. O. Grillo, G. Venora (Eds.).
2. Gohil K.J., Patel J.A. Herb-drug interactions: a review and study based on assessment of clinical case reports in literature. Indian J Pharmacol. 2007, 39:129-139.
3. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001, 61:2163-2175.
4. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75:311-335.
5. Lip G.Y.H. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. J. Thromb. Haemost. 2005, 11:615-626.
6. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood 2010, 115:15-20.
7. Weitz J.I. Blood coagulation NA anticoagulant, fibrinolytic and antiplatelet drugs. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011, 849-876. McGraw-Hill, New York. L. Brunton, B. Chabner, B. Knollman (Eds.).
8. Sawicka-Powierza J., Rogowska-Szadkowska D., Oltarzewska A.M., Chlabicz S. Factors influencing activity of oral anticoagulants. Interactions with drugs and food. Polski Merkuriusz Lekarski 2008, 24:458-462.
9. Nadkarni A., Oldham M.A., Howar M., Berenbaum I. Drug-drug interactions between warfarin and psychotropics: updated review of the literature. Pharmacotherapy 2012, 32:932-942.
10. You J.J., Singer D.E., Howard P.A., Lane D.A., Eckman M.H., Fang M.C., Hylec E.M., Schulman S., Go A.S., Hughes M., Spencer F.A., Manning W.J., Halperin J.L., Lip G.Y. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141:531-575.
11. Ge B., Zhang Z., Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evid. Based Complement. Altern. Med. 2014, 2014:1-18.
12. Das M., Panter L., Connor N., Mills J., Gupta D. The primary care atrial fibrillation (PCAF) service: consultant-led anticoagulation assessment clinics in the primary care setting increase the uptake of anticoagulation therapy in AF patients at high-risk of stroke. Europace 2014, 16.
13. Lijnen H.R., Collen D. Fibrinolysis and the control of hemostasis. The Molecular Basis of Blood Diseases 2001, 740-763. W.B. Saunders Co, Philadelphia. S. Majerus, P. Varmus (Eds.).
14. Spronk H.M., Govers-Riemslag J.W., ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003, 25:1220-1228.
15. Van Dreden P., Rouseau A., Savoure A., Lenormand B., Fontaine S., Vasse M. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. Blood Coagul. Fibrinolysis 2009, 20:635-641.
16. Paoletti A., Gallo E., Benemei S., Vietri M., Lapi F., Volpi R., Ippolito F.M., Gori L., Mugelli A., Firensuoli F., Vannacci A. Interactions between natural health products and oral anticoagulants: spontaneous reports in the Italian surveillance system of natural health products. Evid. Based Complement. Altern. Med. 2011, 2011:5.
17. Coon J.C., Miller T. Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations. Pharmacotherapy 2014, 34:973-990.
18. Lila M.A., Raskin I. Health-related interactions of phytochemicals. J. Food Sci. 2005, 70:20-27.
19. Lambert J.P., Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001, 21:509-512.
20. Amrani S., Harnafi H., Gadi D., Mekhfi H., Legssyer A., Aziz M., Nizard F.M., Bosca L. Vasorelaxant and anti-platelet aggregation effects of aqueous Ocimum basilicum extract. J. Ethnopharmacol. 2009, 125:157-162.
21. Jantan I., Rafi I.A., Jalil J. Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants. Phytomedicine 2005, 12:88-92.
22. Pareek A., Suthar M., Rathore G.S., Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacogn. Rev. 2011, 5:103-110.
23. Oku H., Ueda Y., Iinuma M., Ishiguro K. Inhibitory effects of xanthones from guttiferae plants on PAF-induced hypotension in mice. Planta Med. 2005, 71:90-92.
24. Koshy A.S., Anila L., Vijayalakshmi N.R. Flavonoids from Garcinia cambogia lower lipid levels in hypercholesterolemic rats. Food Chem. 2001, 72:289-294.
25. Nie Z.G., Wang W.J. Effect of ginkgolide B on platelet-activating factor induced activation of rat polymorphonuclear leukocytes. Yao Xue Xue Bao 2003, 38:98-102.
26. Tachjian A., Maria V., Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J. Am. Coll. Cardiol. 2010, 55:515-525.
27. Andersson M., Lindh J. Possible interaction between pomegranate juice and warfarin. Lakartidningen 2012, 109:483.
28. Komperda K.E. Potential interaction between pomegranate juice and warfarin. Pharmacotherapy 2009, 29:1002-1006.
29. Jarvis S., Li C., Bogle R.G. Possible interaction between pomegranate juice and warfarin. Emerg. Med. J. 2010, 27:74-75.
30. Taki Y., Yokotani K., Yamada S., Shinozuka K., Kubota Y., Watanabe W., Umegaki K. Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice. Phytomedicine 2012, 19:177-182.
31. Michalets E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998, 18:84-112.
32. Kaminsky L.S., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 1997, 73:67-74.
33. Dewick P. Medicinal Natural Product - a Biosynthetic Approach 2009, Department of Ecology - Swedish University of Agricultural Science, Switzerland. third ed.
34. Segal R., Pilote L. Warfarin interaction with Matricaria chamomilla. Can. Med. Assoc. J. 2006, 174:1281-1282.
35. Page R.L., Lawrence J.D. Potentiation of warfarin by dong quai. Pharmacotherapy 1999, 19:870-876.
36. Fugh-Berman A. Herb-drug interactions. Lancet 2000, 355:134-138.
37. Fasinu P.S., Bouic P.J., Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol. 2012, 3:69.
38. Tsai H.H., Lin H.W., Simon Pickard A., Tsai H.Y., Mahady G.B. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int. J. Clin. Pract. 2012, 66:1056-1078.
39. Rywaniak J., Luzak B., Podedek A., Dudzinska D., Rozalski M., Watala C. Comparison of cytotoxic and anti-platelet activities of polyphenolic extracts from Arnica montana flowers and Juglans regia husks. Platelets 2015, 26:168-176.
40. Farhadi R., Salehi Balashahri M., Gholami Tileben H., Sadeghi M. Pharmacology of borage (Borago officinalis L.). Int. J. Agron. Plant Prod. 2012, 3:73-77.
41. Izzo A.A. Interactions between herbs and conventional drugs: overview of the clinical data. Med. Princ. Pract. 2012, 21:404-428.
42. Santana L.C., Brito M.R., Oliveira G.L., Cito A.M., Alves C.Q., David J.P., David J.M., Freitas R.M. Mikania glomerata: phytochemical, pharmacological, and neurochemical study. Evid. Based Complement. Altern. Med. 2014, 2014:1-11.
43. Apitz-Castro R., Ledezma E., Escalante J., Jain M.K. The molecular basis of the antiplatelet action of ajoene: direct interaction with the fibrinogen receptor. Biochem. Biophys. Res. Commun. 1986, 141:145-150.
44. Cheng T.O. Not only green tea but also green leafy vegetables inhibit warfarin. Int. J. Cardiol. 2008, 125:101.
45. Moore R.J., Jackson K.G., Minihane A.M. Green tea (Camellia sinensis) catechins and vascular function. Br. J. Nutr. 2009, 102:1790-1802.
46. Sato A.C., Andrade S.A., Brito M.V., Miranda A., Sampaio M.U., Maffei F.H.A., Oliva M.L. Effects of compounds from Passiflora edulis Sims f. flavicarpa juice on blood coagulation and on proteolytic enzymes. Protein Peptide Lett. 2012, 19:501-508.
47. Argento A., Tiraferri E., Marzaloni M. Oral anticoagulants and medicinal plants. An emerging interaction. Ann. Ital. Med. Int. 2000, 15:139-143.
48. Ulbricht C., Chao W., Costa D., Rusie-Semon E., Weussner W., Wood J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr. Drug Metab. 2008, 9:1063-1120.
49. Yuan C.S., Wei G., Dey L., Karrison T., Nahlik L., Maleckar S., Kasza K., Lee M.A., Moss J. Brief communication: american ginseng reduces warfarin's effect in healthy patients: a randomized controlled Trial. Ann. Intern. Med. 2004, 141:23-27.
50. Lee S.H., Ahn Y.M., Ahn S.Y., Doo H.K., Lee B.C. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J. Altern. Complement. Med. 2008, 14:715-721.
51. Rosado M.F. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology 2003, 99:111.
52. Plotnikoff G.A., McKenna D., Watanabe K., Blumenthal M., Plotnikoff G.A., McKenna D. Ginseng and warfarin interactions. Ann. Intern. Med. 2004, 141:893-894.
53. Malati C.Y., Roberton S.M., Hunt J.D., Chairez C., Alfaro R.M., Kovacs J.A., Penzac S.R. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J. Clin. Pharmacol. 2012, 52:932-939.
54. Jiang X., Williams K.M., Liauw W.S., Ammit A.J., Roufogali B.D., Duke C.C., Day R.O., McLachlan A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 2004, 57:592-599.